Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms
-
- Andrea Schmitt
- Department of Psychiatry and Psychotherapy, LMU Munich, Germany;
-
- Daniel Martins-de-Souza
- Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil;
-
- Schahram Akbarian
- Division of Psychiatric Epigenomics, Departments of Psychiatry and Neuroscience, Mount Sinai School of Medicine, New York, USA;
-
- Juliana S. Cassoli
- Laboratory of Neuroproteomics, Department of Biochemistry, Institute of Biology University of Campinas (UNICAMP), Campinas, SP, Brazil;
-
- Hannelore Ehrenreich
- Clinical Neuroscience, Max Planck Institute of Experimental Medicine, DFG Centre for Nanoscale Microscopy & Molecular Physiology of the Brain, Göttingen, Germany;
-
- Andre Fischer
- Research Group for Epigenetics in Neurodegenerative Diseases, German Centre for Neurodegenerative Diseases (DZNE), Göttingen, Germany;
-
- Alfred Fonteh
- Neurosciences, Huntington Medical Research Institutes, Pasadena, CA, USA;
-
- Wagner F. Gattaz
- Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil;
-
- Michael Gawlik
- Department of Psychiatry and Psychotherapy, University of Würzburg, Germany;
-
- Manfred Gerlach
- Centre for Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Germany;
-
- Edna Grünblatt
- Department of Psychiatry and Psychotherapy, University of Würzburg, Germany;
-
- Tobias Halene
- Division of Psychiatric Epigenomics, Departments of Psychiatry and Neuroscience, Mount Sinai School of Medicine, New York, USA;
-
- Alkomiet Hasan
- Department of Psychiatry and Psychotherapy, LMU Munich, Germany;
-
- Kenij Hashimoto
- Division of Clinical Neuroscience, Chiba University Centre for Forensic Mental Health, Chiba, Japan;
-
- Yong-Ku Kim
- Department of Psychiatry, Korea University, College of Medicine, Republic of Korea;
-
- Sophie-Kathrin Kirchner
- Department of Psychiatry and Psychotherapy, LMU Munich, Germany;
-
- Johannes Kornhuber
- Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany;
-
- Theo F.J. Kraus
- Institute of Neuropathology, LMU Munich, Germany;
-
- Berend Malchow
- Department of Psychiatry and Psychotherapy, LMU Munich, Germany;
-
- Juliana M. Nascimento
- Laboratory of Neuroproteomics, Department of Biochemistry, Institute of Biology University of Campinas (UNICAMP), Campinas, SP, Brazil;
-
- Moritz Rossner
- Department of Psychiatry, Molecular and Behavioural Neurobiology, LMU Munich, Germany;
-
- Markus Schwarz
- Institute for Laboratory Medicine, LMU Munich, Germany;
-
- Johann Steiner
- Department of Psychiatry, University of Magdeburg, Magdeburg, Germany;
-
- Leda Talib
- Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil;
-
- Florence Thibaut
- Department of Psychiatry, University Hospital Cochin (site Tarnier), University of Paris-Descartes, INSERM U 894 Centre Psychiatry and Neurosciences, Paris, France;
-
- Peter Riederer
- Center of Psychic Health; Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Germany
-
- Peter Falkai
- Department of Psychiatry and Psychotherapy, LMU Munich, Germany;
書誌事項
- 公開日
- 2016-10-26
- DOI
-
- 10.1080/15622975.2016.1224929
- 公開者
- Informa UK Limited
この論文をさがす
説明
Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response.This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed.Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition.Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice.
収録刊行物
-
- The World Journal of Biological Psychiatry
-
The World Journal of Biological Psychiatry 18 (5), 330-356, 2016-10-26
Informa UK Limited